Skip to content
Quebec News Tribune – Lifestyle
Author:
Pharvaris N.V.
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
July 6, 2026
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
←
Previous Page
1
2